IDV vehicle
36E79725D0046
NEW AWARD FOR EMTRICITABINE 200MG/TENOFOVIR DISOPROXIL FUMARATE 300MG TABLETS WITH AVKARE, LLC. BASE YEAR ORDERING PERIOD IS OCTOBER 6, 2025 TO OCTOBER 5, 2026 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $10.0M |
| Start date | Oct 6, 2025 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 1, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 1, 2026 | P00003 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION |
| Aug 6, 2026 | P00002 | $0 | EXERCISE OPTION YEAR 1, EFFECTIVE 10/06/2026 - 10/05/2027,CONTRACT 36E79725D0046 FOR EMTRICITABINE 200MG/TENOFOVIR DISOPROXIL FUMARATE 300MG TABLETS. |
| Dec 10, 2025 | P00001 | $0 | INCORPORATION OF 2026 SMALL BUSINESS SUBCONTRACTING PLAN INTO CONTRACT 36E79725D0046 - EMTRICITABINE/TENOFOVIR. |
| Jun 30, 2025 | 0 | $0 | NEW AWARD FOR EMTRICITABINE 200MG/TENOFOVIR DISOPROXIL FUMARATE 300MG TABLETS WITH AVKARE, LLC. BASE YEAR ORDERING PERIOD IS OCTOBER 6, 2025 TO OCTOBER 5, 2026 WITH FOUR ONE-YEAR OPTIONS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.